Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer
Status:
Completed
Trial end date:
2014-02-28
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well brivanib alaninate works in treating patients with
cervical cancer that has come back. Brivanib alaninate may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.